Targeting the Leukemia-stroma Interaction in Acute Myeloid Leukemia: Rationale and Latest Evidence

Overview

Journal Ther Adv Hematol

Specialty Hematology

Date 2016 Feb 3

PMID 26834953

Citations 32

Authors

Armin Rashidi

John F Dipersio

Affiliations

Soon will be listed here.

Abstract

The concept of 'niche' has become a focus of attention in hematologic malignancies including acute myeloid leukemia (AML). Similar to normal hematopoietic stem cells, AML cells interact both anatomically and functionally with the stroma within the marrow microenvironment. These interactions have a critical role in the development, progression, and relapse of AML. Chemotherapy resistance is another feature that is at least partially related to AML-stroma interactions. The evidence for safety and efficacy of agents targeting AML-niche interactions is currently limited to preclinical and early phase clinical studies. Examples include CXCR4 inhibitors, hypoxia-inducible agents, and adhesion molecule inhibitors. Agents that target AML-stroma interactions differ from mutation-specific approaches that tend to be limited due to within-individual and between-individual genetic heterogeneity. These agents may be used alone or as chemosensitizers in AML. This novel and rapidly advancing strategy is likely to become an important part of our armamentarium of anti-leukemia treatments in the near future.

Citing Articles

Remodeling of the bone marrow microenvironment during acute myeloid leukemia progression.

Urs A, Goda C, Kulkarni R Ann Transl Med. 2024; 12(4):63.

PMID: 39118939 PMC: 11304419. DOI: 10.21037/atm-23-1824.

Dexamethasone-Induced Fatty Acid Oxidation and Autophagy/Mitophagy Are Essential for T-ALL Glucocorticoid Resistance.

Olivas-Aguirre M, Perez-Chavez J, Torres-Lopez L, Hernandez-Cruz A, Pottosin I, Dobrovinskaya O Cancers (Basel). 2023; 15(2).

PMID: 36672393 PMC: 9856638. DOI: 10.3390/cancers15020445.

Inhibition of IRE1α RNase activity sensitizes patient-derived acute myeloid leukaemia cells to proteasome inhibitors.

Creedican S, Robinson C, Mnich K, Islam M, Szegezdi E, Clifford R J Cell Mol Med. 2022; 26(16):4629-4633.

PMID: 35822520 PMC: 9357667. DOI: 10.1111/jcmm.17479.

Upregulation of hsa-miR-625-5p Inhibits Invasion of Acute Myeloid Leukemia Cancer Cells through ILK/AKT Pathway.

Samieyan Dehkordi S, Mousavi S, Ebrahimi M, Alizadeh S, Hedayati Asl A, Mohammad M Cell J. 2022; 24(2):76-84.

PMID: 35279963 PMC: 8918266. DOI: 10.22074/cellj.2022.7658.

Molecular Systems Architecture of Interactome in the Acute Myeloid Leukemia Microenvironment.

Ayyadurai V, Deonikar P, McLure K, Sakamoto K Cancers (Basel). 2022; 14(3).

PMID: 35159023 PMC: 8833542. DOI: 10.3390/cancers14030756.

References

Nervi B, Ramirez P, Rettig M, Uy G, Holt M, Ritchey J . Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood. 2008; 113(24):6206-14. PMC: 2699239. DOI: 10.1182/blood-2008-06-162123. View

Spoo A, Lubbert M, Wierda W, Burger J . CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood. 2006; 109(2):786-91. DOI: 10.1182/blood-2006-05-024844. View

Bendall L, Daniel A, Kortlepel K, Gottlieb D . Bone marrow adherent layers inhibit apoptosis of acute myeloid leukemia cells. Exp Hematol. 1994; 22(13):1252-60. View

Winkler I, Barbier V, Nowlan B, Jacobsen R, Forristal C, Patton J . Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance. Nat Med. 2012; 18(11):1651-7. DOI: 10.1038/nm.2969. View

Katayama Y, Battista M, Kao W, Hidalgo A, Peired A, Thomas S . Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell. 2006; 124(2):407-21. DOI: 10.1016/j.cell.2005.10.041. View

Dipersio J, Micallef I, Stiff P, Bolwell B, Maziarz R, Jacobsen E . Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and.... J Clin Oncol. 2009; 27(28):4767-73. DOI: 10.1200/JCO.2008.20.7209. View

Chow D, Wenning L, Miller W, Papoutsakis E . Modeling pO(2) distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models. Biophys J. 2001; 81(2):685-96. PMC: 1301545. DOI: 10.1016/S0006-3495(01)75733-5. View

Uy G, Rettig M, Motabi I, McFarland K, Trinkaus K, Hladnik L . A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. 2012; 119(17):3917-24. PMC: 3350358. DOI: 10.1182/blood-2011-10-383406. View

Jin L, Hope K, Zhai Q, Smadja-Joffe F, Dick J . Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006; 12(10):1167-74. DOI: 10.1038/nm1483. View

10.

Layani-Bazar A, Skornick I, Berrebi A, Pauker M, Noy E, Silberman A . Redox modulation of adjacent thiols in VLA-4 by AS101 converts myeloid leukemia cells from a drug-resistant to drug-sensitive state. Cancer Res. 2014; 74(11):3092-103. DOI: 10.1158/0008-5472.CAN-13-2159. View

11.

Krause D, Fulzele K, Catic A, Sun C, Dombkowski D, Hurley M . Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat Med. 2013; 19(11):1513-7. PMC: 3827980. DOI: 10.1038/nm.3364. View

12.

Anguille S, Van Tendeloo V, Berneman Z . Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia. 2012; 26(10):2186-96. DOI: 10.1038/leu.2012.145. View

13.

Rombouts E, Pavic B, Lowenberg B, Ploemacher R . Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood. 2004; 104(2):550-7. DOI: 10.1182/blood-2004-02-0566. View

14.

Buckley C, Amft N, Bradfield P, Pilling D, Ross E, Amara A . Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol. 2000; 165(6):3423-9. DOI: 10.4049/jimmunol.165.6.3423. View

15.

Greenbaum A, Hsu Y, Day R, Schuettpelz L, Christopher M, Borgerding J . CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature. 2013; 495(7440):227-30. PMC: 3600148. DOI: 10.1038/nature11926. View

16.

Peled A, Kollet O, Ponomaryov T, Petit I, Franitza S, Grabovsky V . The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood. 2000; 95(11):3289-96. View

17.

Cogle C, Goldman D, Madlambayan G, Leon R, Masri A, Clark H . Functional integration of acute myeloid leukemia into the vascular niche. Leukemia. 2014; 28(10):1978-1987. PMC: 4167983. DOI: 10.1038/leu.2014.109. View

18.

Hu P, Thinschmidt J, Yan Y, Hazra S, Bhatwadekar A, Caballero S . CNS inflammation and bone marrow neuropathy in type 1 diabetes. Am J Pathol. 2013; 183(5):1608-20. PMC: 3814523. DOI: 10.1016/j.ajpath.2013.07.009. View

19.

Xie Y, Yin T, Wiegraebe W, He X, Miller D, Stark D . Detection of functional haematopoietic stem cell niche using real-time imaging. Nature. 2008; 457(7225):97-101. DOI: 10.1038/nature07639. View

20.

Kuhne M, Mulvey T, Belanger B, Chen S, Pan C, Chong C . BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2012; 19(2):357-66. DOI: 10.1158/1078-0432.CCR-12-2333. View